株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗真菌薬:技術と世界市場

Antifungal Drugs: Technologies and Global Markets

発行 BCC Research 商品コード 117625
出版日 ページ情報 英文 291 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.53円で換算しております。
抗真菌薬:技術と世界市場 Antifungal Drugs: Technologies and Global Markets
出版日: 2020年05月13日 ページ情報: 英文 291 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

抗真菌薬の世界市場は、2019年の146億米ドルから2024年までに176億米ドルまで拡大し、2019年~2024年のCAGRで3.8%の成長が予測されています。市販 (OTC) 抗真菌薬の世界市場は、2019年の74億米ドルから2024年までに90億米ドルまで拡大し、2019年~2024年のCAGRで3.9%の成長が予測されています。処方抗真菌薬の世界市場は、2019年の72億米ドルから2024年までに86億米ドルまで拡大し、2019年~2024年のCAGRで3.7%の成長が予測されています。

当レポートでは、世界の抗真菌薬市場について調査分析し、市場概要、市場の内訳、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 サマリーとハイライト

  • 抗真菌薬の世界市場の収益分析
  • 地域の概要
  • 市場セグメント分析
  • 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場シェア分析

第3章 菌類と抗真菌薬市場のイントロダクション

  • 菌類のイントロダクション
  • 菌類の分類
  • ツボカビ門
  • コウマクノウキン門
  • ネオカリマスティクス菌門
  • 微胞子虫門
  • 子嚢菌門
  • 担子菌門
  • グロムス菌門
  • 適応範囲:人間の医療、など

第4章 共通の環境における菌類

  • カビとそれに関連する人間の問題
  • 環境のカビが固有の問題になる理由
  • 環境の菌類とカビによる健康上のリスク
  • 環境のカビ
  • オルタナリア
  • アスペルギルス
  • クラドスポリウム
  • ペニシリウム、など

第5章 抗真菌薬の分析

  • 抗真菌薬のイントロダクション
  • 抗真菌薬の分類
  • 全身性抗真菌薬
  • ポリエン抗生物質
  • アゾール系抗真菌薬
  • エキノカンジン
  • 代謝拮抗剤:フルシトシン (5-FC)
  • その他の全身性抗真菌薬
  • 局所性抗真菌薬
  • 局所性ポリエン抗生物質、など

第6章 新しい革新的な抗真菌薬:現在の開発、臨床試験、製品パイプライン

  • 新しい革新的な抗真菌薬の必要性
  • 新しい抗真菌薬の開発に対する戦略的アプローチ
  • 生理活性化合物
  • ナノ構造の抗真菌薬
  • 医薬品リポジショニング
  • 真菌性疾患に対するワクチン開発
  • 人工知能ベースのプラットフォーム技術
  • 新興の標的と分子足場、など

第7章 抗真菌薬の世界市場

  • イントロダクション
  • 市場収益分析
  • 世界市場の収益分析
  • 地域の概要
  • 抗真菌薬の治療と技術における主な開発と動向
  • 処方抗真菌薬
  • OTC抗真菌薬
  • 市場シェア分析

第8章 抗真菌薬の北米市場

第9章 抗真菌薬の欧州市場

第10章 抗真菌薬のアジア太平洋地域市場

第11章 抗真菌薬のラテンアメリカ市場

第12章 抗真菌薬の中東/アフリカ市場

第13章 企業プロファイル

第14章 付録A

第15章 付録B

第16章 付録C

第17章 付録D

第18章 付録E

図表

List of Tables

  • Summary Table D : Global Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Summary Table B : Global Market for Antifungal Drugs, by Region, Through 2024
  • Summary Table A : Global Market for Antifungal Drugs, by Segment, Through 2024
  • Summary Table C : Global Market Shares of Antifungal Drugs, by Region, 2019
  • Summary Table E : Global Market for OTC Antifungal Drugs, by Type, Through 2024
  • Summary Table F : Global Market Shares of Antifungal Drugs, by Company, 2019
  • Table 1 : Statistics on the Ten Most Significant Invasive Fungal Infections
  • Table 2 : Major Clinical Manifestations of Histoplasmosis and Associated Risk Factors
  • Table 3 : Morphologic Features of Fungi and Pseudofungal Infections of Unusual Fungi or of Fungi with Uncertain Etiology
  • Table 4 : Risk Factors Associated with Human Fungal Infections
  • Table 5 : Common Symptoms Associated with Environmental Fungi and Molds
  • Table 6 : Risk Factors Associated with Environmental Fungi and Molds
  • Table 7 : Common Locations of the Sources of Environmental Molds
  • Table 8 : History of Antifungal Therapy
  • Table 9 : Patents on Amphotericin B and Their Expiration Dates
  • Table 10 : Approved Fluconazole Prescription Products
  • Table 11 : Patents on Itraconazole and Their Expiration Dates
  • Table 12 : Patents on Voriconazole and Their Expiration Dates
  • Table 13 : Approved Voriconazole Prescription Products
  • Table 14 : Patents on Posaconazole and Their Expiration Dates
  • Table 15 : Patents on Ketoconazole and Their Expiration Dates
  • Table 16 : Approved Miconazole OTC Products
  • Table 17 : International Clotrimazole Brand Names
  • Table 18 : Approved Generic Prescriptions for Clotrimazole
  • Table 19 : Patents on Caspofungin and Their Expiration Dates
  • Table 20 : Patents on Micafungin and Their Expiration Dates
  • Table 21 : Patents on Anidulafungin and Their Expiration Dates
  • Table 22 : Antifungal Compounds with Novel Targets in Development
  • Table 23 : Global Market for Antifungal Drugs, by Segment, Through 2024
  • Table 24 : Global Market for Antifungal Drugs, by Region, Through 2024
  • Table 25 : Global Market Shares of Antifungal Drugs, by Region, 2019
  • Table 26 : Global Market Shares of Antifungal Drugs, by Company, 2019
  • Table 27 : North American Market for Antifungal Drugs, by Segment, Through 2024
  • Table 28 : North American Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 29 : North American Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 30 : North American Market for Antifungal Drugs, by Country, Through 2024
  • Table 31 : U.S. Market for Antifungal Drugs, by Segment, Through 2024
  • Table 32 : U.S. Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 33 : U.S. Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 34 : Canadian Market for Antifungal Drugs, by Segment, Through 2024
  • Table 35 : Canadian Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 36 : Canadian Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 37 : North American Market Shares of Antifungal Drugs, by Company, 2019
  • Table 38 : European Market for Antifungal Drugs, by Segment, Through 2024
  • Table 39 : European Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 40 : European Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 41 : European Market for Antifungal Drugs, by Country, Through 2024
  • Table 42 : French Market for Antifungal Drugs, by Segment, Through 2024
  • Table 43 : French Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 44 : French Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 45 : German Market for Antifungal Drugs, by Segment, Through 2024
  • Table 46 : German Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 47 : German Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 48 : Italian Market for Antifungal Drugs, by Segment, Through 2024
  • Table 49 : Italian Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 50 : Italian Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 51 : Spanish Market for Antifungal Drugs, by Segment, Through 2024
  • Table 52 : Spanish Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 53 : Spanish Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 54 : U.K. Market for Antifungal Drugs, by Segment, Through 2024
  • Table 55 : U.K. Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 56 : U.K. Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 57 : Benelux Market for Antifungal Drugs, by Segment, Through 2024
  • Table 58 : Benelux Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 59 : Benelux Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 60 : Scandinavian Market for Antifungal Drugs, by Segment, Through 2024
  • Table 61 : Scandinavian Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 62 : Scandinavian Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 63 : Rest-of-European Market for Antifungal Drugs, by Segment, Through 2024
  • Table 64 : Rest-of-European Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 65 : Rest-of-European Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 66 : European Market Shares of Antifungal Drugs, by Company, 2019
  • Table 67 : Overview of Healthcare in India
  • Table 68 : Asia-Pacific Market for Antifungal Drugs, by Segment, Through 2024
  • Table 69 : Asia-Pacific Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 70 : Asia-Pacific Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 71 : Asia-Pacific Market for Antifungal Drugs, by Country, Through 2024
  • Table 72 : Indian Market for Antifungal Drugs, by Segment, Through 2024
  • Table 73 : Indian Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 74 : Indian Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 75 : Chinese Market for Antifungal Drugs, by Segment, Through 2024
  • Table 76 : Chinese Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 77 : Chinese Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 78 : Japanese Market for Antifungal Drugs, by Segment, Through 2024
  • Table 79 : Japanese Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 80 : Japanese Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 81 : South Korean Market for Antifungal Drugs, by Segment, Through 2024
  • Table 82 : South Korean Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 83 : South Korean Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 84 : Rest of Asia-Pacific Market for Antifungal Drugs, by Segment, Through 2024
  • Table 85 : Rest of Asia-Pacific Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 86 : Rest of Asia-Pacific Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 87 : Asia-Pacific Market Shares of Antifungal Drugs, by Company, 2019
  • Table 88 : Latin American Market for Antifungal Drugs, by Segment, Through 2024
  • Table 89 : Latin American Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 90 : Latin American Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 91 : Latin American Market for Antifungal Drugs, by Country, Through 2024
  • Table 92 : Argentinian Market for Antifungal Drugs, by Segment, Through 2024
  • Table 93 : Argentinian Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 94 : Argentinian Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 95 : Brazilian Market for Antifungal Drugs, by Segment, Through 2024
  • Table 96 : Brazilian Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 97 : Brazilian Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 98 : Chilean Market for Antifungal Drugs, by Segment, Through 2024
  • Table 99 : Chilean Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 100 : Chilean Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 101 : Mexican Market for Antifungal Drugs, by Segment, Through 2024
  • Table 102 : Mexican Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 103 : Mexican Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 104 : Rest of Latin American Market for Antifungal Drugs, by Segment, Through 2024
  • Table 105 : Rest of Latin American Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 106 : Rest of Latin American Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 107 : Latin American Market Shares of Antifungal Drugs, by Company, 2019
  • Table 108 : Number of Saudi Arabian Hospitals and Beds, by Sector and Administrative Region
  • Table 109 : Middle Eastern/African Market for Antifungal Drugs, by Segment, Through 2024
  • Table 110 : Middle Eastern/African Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 111 : Middle Eastern/African Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 112 : Middle Eastern/African Market for Antifungal Drugs, by Region/Country, Through 2024
  • Table 113 : African Market for Antifungal Drugs, by Segment, Through 2024
  • Table 114 : African Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 115 : African Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 116 : Middle Eastern Market for Antifungal Drugs, by Segment, Through 2024
  • Table 117 : Middle Eastern Market for Prescription Antifungal Drugs, by Type, Through 2024
  • Table 118 : Middle Eastern Market for OTC Antifungal Drugs, by Type, Through 2024
  • Table 119 : Middle Eastern/African Market Shares of Antifungal Drugs, by Company, 2019
  • Table 120 : Astellas Pharma Inc.: Revenues, by Drug, 2017-2019
  • Table 121 : Bausch Health Companies Inc.: Revenues, by Segment, 2017-2019
  • Table 122 : Bayer AG: Revenues, by Division, 2017-2019
  • Table 123 : Bayer AG: Revenues, by Best Selling Products in the Consumer Health Division, 2018-2019
  • Table 124 : Cidara Therapeutics Inc.: Revenues, by Type, 2016-2019
  • Table 125 : Dr. Reddy's Laboratories: Revenues, by Region and Division, 2017-2019
  • Table 126 : Gilead Sciences Inc.: Revenues, by Product Segment, 2016-2019
  • Table 127 : Merck & Co., Inc.: Revenues, by Antifungal Product Segment, 2016-2019
  • Table 128 : Mylan Laboratories Inc.: Revenues, by Segment, 2016-2019
  • Table 129 : Pfizer Inc.: Revenues, by Segment, 2017-2019
  • Table 130 : Vfend: Revenues, by Product Segment, 2017-2019
  • Table 131 : Sanofi S.A.: Revenues, by Segment, 2017-2019
  • Table 132 : Teva Pharmaceutical Industries Ltd.: Revenues, 2017-2019
  • Table 133 : Tier 1: Major Multinational Medical Device Companies: Contact Details
  • Table 134 : Tier 2: Entrepreneurial Small and Medium-Sized Enterprises Contact Details
  • Table 135 : Studies Conducted in the Design of Antifungal Vaccine Strategy
  • Table 136 : Government Regulatory Agencies, Professional Organizations and Regulatory Acronyms
  • Table 137 : Commonly Used Acronyms and Terms used for Antifungal Drugs and Antifungal Drug Treatments

List of Figures

  • Summary Figure A : Global Market for Antifungal Drugs, by Segment, 2018-2024
  • Summary Figure B : Global Market for Antifungal Drugs, by Region, 2018-2024
  • Summary Figure C : Global Market Shares of Antifungal Drugs, by Region, 2019
  • Summary Figure D : Global Market for Prescription Antifungal Drugs, by Type, 2018-2024
  • Summary Figure E : Global Market for OTC Antifungal Drugs, by Type, 2018-2024
  • Figure 1 : Schematic of Fungi Classification
  • Figure 2 : Worldwide Distribution of Reported Cases of C. auris, 2018
  • Figure 3 : Number of Reported Cryptococcosis Cases, 1998-2017
  • Figure 4 : Global Burden of HIV-Related Cryptococcal Meningitis, by Region
  • Figure 5 : County-Specific Incidence of Histoplasmosis for the 12 U.S. States for Which Surveillance Data Were Available, 2011-2014
  • Figure 6 : Timeline of Antifungal Drug Development, 1950-2020
  • Figure 7 : Sphingolipid Biosynthetic Pathways
  • Figure 8 : Strategic Approach to the Development of Vaccines for Fungal Infections
  • Figure 9 : Principle Categories of Vaccines for Fungal Infections
  • Figure 10 : Mycovia Pharmaceuticals: Current Product Pipeline
  • Figure 11 : Ibrexafungerp Development Pipeline, 2018-2020
  • Figure 12 : Global Market for Antifungal Drugs, by Segment, 2018-2024
  • Figure 13 : Global Market Shares of Antifungal Drugs, by Segment, 2019
  • Figure 14 : Global Market Shares of Antifungal Drugs, by Region, 2019
  • Figure 15 : North American Market for Prescription Antifungal Drugs, by Type, 2019
  • Figure 16 : North American Market for OTC Antifungal Drugs, by Type, 2019
  • Figure 17 : Mutual Recognition Procedure
  • Figure 18 : Decentralized Procedure
  • Figure 19 : European Market for Prescription Antifungal Drugs, by Type, 2019
  • Figure 20 : European Market for OTC Antifungal Drugs, by Type, 2019
  • Figure 21 : Flowchart of New Drug Development and Approval Process in Japan
  • Figure 22 : Timeline of the Standard Process of New Drug Approvals in Japan
  • Figure 23 : Chinese Drug Funding/Reimbursement Approval Procedure
  • Figure 24 : The Chinese Healthcare System
  • Figure 25 : Asia-Pacific Market for Prescription Antifungal Drugs, by Type, 2019
  • Figure 26 : Asia-Pacific Market for OTC Antifungal Drugs, by Type, 2019
  • Figure 27 : Argentinian Regulatory Drug Approval Procedure, Standard Review 120-240 Business Days for Approval
  • Figure 28 : Latin American Market for Prescription Antifungal Drugs, by Type, 2019
  • Figure 29 : Latin American Market for OTC Antifungal Drugs, by Type, 2019
  • Figure 30 : Current Structure of the Healthcare Sectors in Saudi Arabia, 2018
  • Figure 31 : Middle Eastern/African Market for Prescription Antifungal Drugs, by Type, 2019
  • Figure 32 : Middle Eastern/African Market for OTC Antifungal Drugs, by Type, 2019
目次
Product Code: PHM029G

Highlights:

The global market for antifungal drugs should grow from $14.6 billion in 2019 to reach $17.6 billion by 2024, at a compound annual growth rate (CAGR) of 3.8% for the forecast period of 2019-2024.

The global market for over-the-counter (OTC) antifungal drugs should grow from $7.4 billion in 2019 to reach $9.0 billion by 2024, at a CAGR of 3.9% for the forecast period of 2019-2024.

The global market for prescription antifungal drugs should grow from $7.2 billion in 2019 to reach $8.6 billion by 2024, at a CAGR of 3.7% for the forecast period of 2019-2024.

Report Scope:

The aim of this report is to initially conduct a review of the antifungal drugs currently available, explore the issues facing the use of antifungal drugs and review some of the latest developments of new and innovative antifungal drugs, their technologies and their intended clinical applications. The key objective is also to conduct and provide an analysis of the market value, growth rates, market shares and market development, and examine the market dynamics and market factors influencing the growth and development of this market.

This report also looks at the challenges and potential threats facing the industry and the factors influencing the market shares of the major market suppliers as well as smaller manufacturers in local markets. The emphasis of this report is to provide the reader with -

  • A detailed analysis of the revenues and forecasts for the global antifungal drug market with a more-detailed analysis and forecast of the revenues for the global market sub-divided by major market sub-segments by geographic region and selected country.
  • A detailed analysis of the global market share together with a more detailed analysis of the market share by geographic regions and selected country.

In addition, this analysis provides a -

  • Detailed review of the current products, their indications and availability for all the market segments identified.
  • Profile of the individual market sub-segments within the major market segments analyzed and the distinguishing features of each of the market sub-segments.
  • Review of the major market opportunities through the recognition of specific high-growth and emerging market opportunities.
  • Brief description of the historical development for each of the major market segments.
  • Profile of the leading suppliers of antifungal drugs together with related information about specific products.

The study will allow the reader to -

  • Evaluate the effect of strategic factors such as technology-driven change and industry consolidation for the antifungal drug market.
  • Investigate the current market dynamics that are driving change in the antifungal drug market.
  • Assess future growth opportunities in the antifungal drug market.
  • Review the main products in each sector and plan a product entry strategy in line with the strengths and weaknesses of the competition.
  • Realize an individual company's position in the market and to gain insight into the future of the market and the opportunities that exist.

The analysis includes the use of charts and graphs measuring product growth and trends within the marketplace. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report.

Report Includes:

  • 116 data tables and 27 additional tables
  • An overview of the global markets for antifungal drugs within the pharmaceuticals industry
  • Analyses of the global market trends, with data corresponding to market size from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Comparative study of the two primary segments of antifungal medications - over-the-counter (OTC) and prescription based - and issues facing the use of these products
  • Briefing about therapeutics in early development such as new molecular and biological entities from traditional pharmaceutical sources, naturally derived synthetic chemicals, and biological sources
  • Review of antifungal agents and their classification based on the mechanism of action, approved therapeutic products and relevant patents with their expiration dates
  • Information pertaining to R&D efforts, breakthrough therapy innovations, clinical trials of novel drug developments, their technologies and intended clinical applications
  • Market share analysis of leading suppliers of antifungal drugs with related information about specific products, and their key competitive landscape
  • Descriptive company profiles of major market players, including Astellas Pharma Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., Gilead Sciences Inc., Janssen Pharmaceuticals Inc. (Johnson & Johnson), Pfizer Inc., Sanofi S.A., and Merck & Co., Inc.

Table of Contents

Chapter 1 Introduction

  • Introduction
  • Scope of the Report
  • Methodology and Information Sources
  • Primary Data and Information Gathering
  • Secondary Data and Information Gathering
  • Market Revenue Forecasts
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

  • Global Market Revenue Analysis for Antifungal Drugs
  • Regional Overview
  • Market Segment Review
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Share Analysis

Chapter 3 Introduction to Fungi and the Antifungal Drug Market

  • Introduction to Fungi
  • Classification of Fungi
  • Chytridiomycota
  • Blastocladiomycota
  • Neocallimastigomycota
  • Microsporidia
  • Ascomycota (Sac Fungi)
  • Basidiomycota (Club Fungi)
  • Glomeromycota
  • Scope of Application: Human Healthcare
  • Types and Descriptions of Fungi Diseases in Humans
  • Aspergillosis
  • Blastomycosis
  • Candidiasis
  • Coccidioidomycosis (Valley Fever)
  • Coccidioidomycosis (Cryptococcosis)
  • Dermatophytosis
  • Fungal Infections of the Eye
  • Histoplasmosis
  • Onychomycosis (Fungal Nail Infections)
  • Mucormycosis (Zygomycosis)
  • Mycetoma
  • Paracoccidioidomycosis
  • Pneumocystis Pneumonia
  • Pseudallescheriasis
  • Sporotrichosis
  • Rare Fungal Infections and Disorders
  • Risk Factors Associated with Human Fungal Infections
  • Use of Antibiotics
  • Use of Corticosteroids
  • Specific Medical Conditions
  • Central Line-Associated Bloodstream Infections
  • Surgery
  • Organ Transplantation
  • Environmental Factors
  • Hereditary Factors
  • Hospitalization

Chapter 4 Common Environmental Fungi

  • Molds and the Human Issues Associated with Them
  • Why Environmental Mold is a Unique Problem
  • Health Risks due to Environmental Fungi and Mold
  • Environmental Molds
  • Alternaria
  • Aspergillus
  • Cladosporium
  • Penicillium
  • Eurotium
  • Rhizopus
  • Mucor
  • Geotrichum
  • Fusarium
  • Stachybotrys
  • Wallemia
  • Trichothecium
  • Scopulariopsis Brevicaulis
  • Scytalidium Dimidiatum
  • Trichoderma
  • Paecilomyces Variotii

Chapter 5 Review of Antifungal Agents

  • Introduction to Antifungal Agents
  • Classification of Antifungal Agents
  • Systemic Antifungal Drugs
  • Polyene Antibiotics
  • Azole Antifungals
  • Echinocandins
  • Antimetabolite: Flucytosine (5-FC)
  • Other Systemic Antifungal Agents
  • Topical Antifungal Drugs
  • Topical Polyene Antibiotics
  • Azoles-Imidazole
  • Others
  • Naturally Occurring Alternatives

Chapter 6 New and Innovative Antifungals: Current Developments, Clinical Trials and Product Pipelines

  • The Need for New and Innovative Antifungals
  • Strategic Approach to the Development of New Antifungal Agents
  • Identification of Bioactive Compounds
  • Nanostructured Antifungals
  • Drug Repositioning
  • Vaccine Development Against Fungal Diseases
  • Artificial Intelligence-Based Platform Technology (FungalAi)
  • Emerging Targets and Molecular Scaffolds
  • New Antifungal Drugs in Development
  • Most Notable Antifungal Compounds
  • Specific Company Product Pipelines
  • Mycovia Pharmaceuticals
  • Amplyx Pharmaceuticals
  • F2G
  • NovaBiotics Ltd.
  • Appili Therapeutics Inc.
  • Scynexis Inc.
  • Bright Angel Therapeutics
  • Valley Fever Solutions

Chapter 7 Global Market for Antifungal Medications

  • Introduction
  • Market Revenue Analysis
  • Global Market Revenue Analysis
  • Regional Overview
  • Major Developments and Trends in Antifungal Drug Treatment and Technologies
  • Prescription Antifungal Drugs
  • OTC Antifungal Drugs
  • Market Share Analysis

Chapter 8 North American Market for Antifungal Drugs

  • Introduction
  • Regulatory and Legislative Requirements
  • United States
  • Canada
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Analysis
  • North America Market Revenue Analysis
  • Regional Overview
  • Individual Markets
  • Market Share Analysis

Chapter 9 European Market for Antifungal Drugs

  • Introduction
  • Regulatory and Legislative Requirements
  • Mutual Recognition Procedure
  • Centralized Procedure
  • Decentralized Procedure
  • European Suspension of Marketing Authorizations for Oral Ketoconazole
  • Over-the-Counter Antifungal Drug Products
  • The Russian Federation
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Analysis
  • Market Revenue Analysis
  • Regional Overview
  • Individual Markets
  • Market Share Analysis

Chapter 10 Asia-Pacific Market for Antifungal Drugs

  • Introduction
  • Regulatory and Legislative Requirements
  • Japan
  • China
  • India
  • South Korea
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Analysis
  • Market Revenue Analysis
  • Regional Overview
  • Individual Markets
  • Market Share Analysis

Chapter 11 Latin American Market for Antifungal Drugs

  • Introduction
  • Regulatory and Legislative Requirements
  • Brazil
  • Argentina
  • Mexico
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Analysis
  • Market Revenue Analysis
  • Regional Overview
  • Individual Markets
  • Market Share Analysis

Chapter 12 Middle Eastern/African Market for Antifungal Drugs

  • Introduction
  • Regulatory and Legislative Requirements
  • South Africa
  • Saudi Arabia
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Analysis
  • Market Revenue Analysis
  • Regional Overview
  • Individual Markets
  • Market Share Analysis

Chapter 13 Company Profiles

  • Introduction
  • Tier 1: Manufacturers of Prescription Pharmaceuticals
  • ANACOR PHARMACEUTICALS, INC.
  • ASTELLAS PHARMA INC.
  • BAUSCH HEALTH COMPANIES INC.
  • BAYER AG
  • CIDARA THERAPEUTICS INC.
  • DR. REDDY'S LABORATORIES LTD.
  • ENZON PHARMACEUTICALS, INC.
  • FERRER INTERNACIONAL S.A.
  • GALDERMA PHARMA S.A.
  • GILEAD SCIENCES INC.
  • GLENMARK PHARMACEUTICALS LTD.
  • JANSSEN PHARMACEUTICALS INC. (JOHNSON & JOHNSON)
  • LEADIANT BIOSCIENCES INC.
  • MERCK & CO., INC.
  • MERZ PHARMA GMBH & CO. KGAA
  • MOBERG PHARMA AB
  • MYLAN LABORATORIES INC.
  • PFIZER INC.
  • SANOFI S.A.
  • TARO PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICALS INDUSTRIES LTD.

Chapter 14 Appendix A

  • Tier 1: Large Multinational Companies and Leading Market Share Holders
  • Company Contact Details

Chapter 15 Appendix B

  • Tier 2: Entrepreneurial Small and Medium-Sized Enterprises
  • Company Addresses and Contact Details

Chapter 16 Appendix C

  • Research Studies in the Design of Antifungal Vaccine Strategy

Chapter 17 Appendix D

  • Government Regulatory Agencies, Professional Organizations and Regulatory Acronyms

Chapter 18 Appendix E

  • Commonly Used Acronyms and Terms used for Antifungal Drugs and Antifungal Drug Treatments